{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:11:51Z","timestamp":1780445511193,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070826"],"award-info":[{"award-number":["82070826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtn.2025.102506","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:55:32Z","timestamp":1741316132000},"page":"102506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AAV-mediated GBA1 and GDNF rescue neurological defects in a murine model of neuronopathic Gaucher disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Yuan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingguo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-5766","authenticated-orcid":false,"given":"Guangzuo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102506_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","article-title":"Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes","volume":"132","author":"Daykin","year":"2021","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.934820","article-title":"Neuronopathic Gaucher disease: Beyond lysosomal dysfunction","volume":"15","author":"Ar\u00e9valo","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib6","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79830","article-title":"Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy","volume":"11","author":"Boddupalli","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.omtn.2025.102506_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/brain\/aws095","article-title":"Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease","volume":"135","author":"Vitner","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2025.102506_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","article-title":"Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease","volume":"20","author":"Farfel-Becker","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102506_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtn.2025.102506_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/15548627.2018.1427396","article-title":"Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease","volume":"14","author":"Garc\u00eda-Sanz","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.omtn.2025.102506_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040364","article-title":"GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches","volume":"8","author":"Riboldi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102506_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102506_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.410200208","article-title":"Type 2 and type 3 Gaucher disease: a morphological and biochemical study","volume":"20","author":"Kaye","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102506_bib14","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036434","article-title":"Cell Death and Neurodegeneration","volume":"12","author":"Andreone","year":"2020","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.omtn.2025.102506_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: Basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102506_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102506_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cells11081261","article-title":"GBA Variants and Parkinson Disease: Mechanisms and Treatments","volume":"11","author":"Smith","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102506_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","article-title":"Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity","volume":"46","author":"Gupta","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.omtn.2025.102506_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","article-title":"Gene therapy for Mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nrg963","article-title":"Enzyme replacement and enhancement therapies: lessons from lysosomal disorders","volume":"3","author":"Desnick","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102506_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00431-001-0859-7","article-title":"Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease","volume":"162","author":"Migita","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtn.2025.102506_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1010514614570","article-title":"Management of neuronopathic Gaucher disease: a European consensus","volume":"24","author":"Vellodi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","article-title":"Clinical and genetic study of Japanese patients with type 3 Gaucher disease","volume":"97","author":"Tajima","year":"2009","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtn.2025.102506_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41386-023-01717-x","article-title":"The role of neurotrophic factors in novel, rapid psychiatric treatments","volume":"49","author":"Kim","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.omtn.2025.102506_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3538","article-title":"GDNF rescues the fate of neural progenitor grafts by attenuating Notch signals in the injured spinal cord in rodents","volume":"12","author":"Khazaei","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102506_bib29","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1093\/brain\/awad087","article-title":"CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress","volume":"146","author":"De Lorenzo","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2025.102506_bib30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ymthe.2019.08.005","article-title":"SINEUP Non-coding RNA Targeting GDNF Rescues Motor Deficits and Neurodegeneration in a Mouse Model of Parkinson's Disease","volume":"28","author":"Espinoza","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00441-020-03269-8","article-title":"GDNF clinical trials for Parkinson's disease: a critical human dimension","volume":"382","author":"Gash","year":"2020","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.omtn.2025.102506_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3233\/JPD-202004","article-title":"GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop","volume":"10","author":"Barker","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00441-020-03287-6","article-title":"GDNF synthesis, signaling, and retrograde transport in motor neurons","volume":"382","author":"Cintr\u00f3n-Col\u00f3n","year":"2020","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.omtn.2025.102506_bib34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102506_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fnmol.2017.00405","article-title":"Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis","volume":"10","author":"Tosolini","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib37","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: A review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JND-200531","article-title":"Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy","volume":"8","author":"Cappella","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102057","article-title":"Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection","volume":"34","author":"Chen","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102506_bib40","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102506_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.4751","article-title":"Delineating pathological pathways in a chemically induced mouse model of Gaucher disease","volume":"239","author":"Vardi","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.omtn.2025.102506_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010112","article-title":"Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease","volume":"18","author":"Bondar","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102506_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1101\/gad.188326.112","article-title":"Astrocytes and disease: a neurodevelopmental perspective","volume":"26","author":"Molofsky","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2025.102506_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5607\/en.2016.25.5.233","article-title":"Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS","volume":"25","author":"Lee","year":"2016","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.omtn.2025.102506_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.666737","article-title":"The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?","volume":"12","author":"MacMahon Copas","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtn.2025.102506_bib46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102506_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41439-024-00282-z","article-title":"Allele frequency of pathogenic variants causing acid sphingomyelinase deficiency and Gaucher disease in the general Japanese population","volume":"11","author":"Sako","year":"2024","journal-title":"Hum. Genome Var."},{"key":"10.1016\/j.omtn.2025.102506_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: a comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.omtn.2025.102506_bib49","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"2015","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omtn.2025.102506_bib50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1089\/hum.2023.067","article-title":"Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease","volume":"34","author":"De","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib51","article-title":"Protocol for the neonatal intracerebroventricular delivery of adeno-associated viral vectors for brain restoration of MECP2 for Rett syndrome","volume":"5","author":"Yang","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omtn.2025.102506_bib52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/01926233221101309","article-title":"Intrathecal sc-AAV9-CB-GFP: Systemic Distribution Predominates Following Single-Dose Administration in Cynomolgus Macaques","volume":"50","author":"Meseck","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2025.102506_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102506_bib55","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omtn.2025.102506_bib56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2025.102506_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.immuni.2023.01.008","article-title":"Direct activation of microglia by \u03b2-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease","volume":"56","author":"Shimizu","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102506_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awaa321","article-title":"The synapse in traumatic brain injury","volume":"144","author":"Jamjoom","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2025.102506_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JPD-150769","article-title":"Retrograde Axonal Degeneration in Parkinson Disease","volume":"6","author":"Tagliaferro","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib60","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer's disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102506_bib61","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201898960","article-title":"Parkinson's disease: convergence on synaptic homeostasis","volume":"37","author":"Soukup","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.omtn.2025.102506_bib62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102506_bib63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molmed.2003.08.006","article-title":"Huntington's disease: a synaptopathy?","volume":"9","author":"Li","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2025.102506_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103082","article-title":"Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases","volume":"19","author":"Chi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102506_bib65","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/mds.28258","article-title":"GDNF\/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons","volume":"35","author":"Chmielarz","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2025.102506_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2022.104846","article-title":"The PI3K-AKT pathway: A plausible therapeutic target in Parkinson's disease","volume":"129","author":"Goyal","year":"2023","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.omtn.2025.102506_bib67","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1016\/j.febslet.2015.11.006","article-title":"GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease","volume":"589","author":"Kramer","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2025.102506_bib68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST20220770","article-title":"Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the \u03b1-synuclein accumulation in Parkinson's disease","volume":"51","author":"Er","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omtn.2025.102506_bib69","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11064-016-2044-4","article-title":"AKT\/GSK3\u03b2 Signaling in Glioblastoma","volume":"42","author":"Majewska","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.omtn.2025.102506_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2019.03.009","article-title":"Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review","volume":"169","author":"Dinda","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102506_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2018.00073","article-title":"The Role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 Signaling in Parkinson's Disease Dementia","volume":"12","author":"Yang","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.851135","article-title":"Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications","volume":"14","author":"Zheng","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109879","article-title":"Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease","volume":"78","author":"Allende","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.omtn.2025.102506_bib74","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.3233\/JPD-212739","article-title":"Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.omtn.2025.102506_bib75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","article-title":"Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders","volume":"24","author":"Brandebura","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrn3505","article-title":"BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases","volume":"14","author":"Lu","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2025.102506_bib77","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.omtm.2021.02.019","article-title":"Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system","volume":"21","author":"Meng","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102506_bib78","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkae401","article-title":"rAAV capsid mutants eliminate leaky expression from DNA donor template for homologous recombination","volume":"52","author":"Ling","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102506_bib79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-6588-5_6","article-title":"Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9","volume":"1521","author":"Kohlbrenner","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102506_bib80","first-page":"3634","article-title":"Isolation and culture of hippocampal neurons from prenatal mice","author":"Seibenhener","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2025.102506_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T04:44:10Z","timestamp":1763354650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2162253125000605"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102506","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-mediated GBA1 and GDNF rescue neurological defects in a murine model of neuronopathic Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102506"}}